Project Grant R01CA302397
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $580K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Bronx, NY 10461, USA
Similar Awards
- The National Cancer Institute, a division of the Department of Health and Human Services, awarded a cooperative agreement totaling $681,310 to The Trustees of Columbia University in the City of New York on June 24, 2026, under the Cancer Biology Research program (CFDA 93.396). The funded research investigates mechanisms that promote bone metastasis in prostate cancer, the major cause of death in metastatic prostate cancer patients. Columbia will use genetically-engineered mouse models (GEMMs) to...
- The National Cancer Institute awarded New York University $595,993 on July 16, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop integrated biologic technologies for selective inhibition of intracellular oncoproteins. The project aims to establish a platform technology that enables direct and selective manipulation of intracellular molecules, particularly driver oncoproteins and their interactions, with the long-term goal of addressing undruggable targets in cancer....
- The National Cancer Institute, under the Department of Health and Human Services, awarded The Research Foundation For The State University Of New York (operating as Stony Brook University) $498,775 under Cancer Biology Research (CFDA 93.396) on July 1, 2026. The award funds investigation of targetable mechanisms driving altered cell states in castration-resistant prostate cancer. The project dissects the emergence of a specific cellular subtype in early-stage prostate cancer capable of...
- The National Cancer Institute awarded Yale University $560,087 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to define and target mechanisms of the neurolysin-KIF11-WNT3A axis driving therapy resistance in prostate cancer. The award funds research into how prostate cancer cells adapt to androgen receptor-targeted therapies and remodel the tumor microenvironment to undermine therapeutic activity. The work will comprehensively define the molecular mechanisms by...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded New York University $701,574 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate APOBEC3-induced mutagenesis in cancer development and therapy resistance. The funded research develops experimental and bioinformatics methods to track de novo generation of specific mutational signatures (SBS2 and SBS13) induced by individual...
- The National Cancer Institute awarded Weill Medical College of Cornell University $169,291 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to characterize the cooperative role of E2F1 and interacting proteins in driving advanced prostate cancer. The project investigates the molecular mechanisms underlying neuroendocrine prostate cancer (NEPC), an aggressive androgen receptor-independent transformation of prostate adenocarcinoma that develops resistance to...
- The National Cancer Institute awarded The Trustees of Columbia University in the City of New York $613,866 on August 17, 2026, under the Cancer Biology Research program (CFDA 93.396) to conduct research on epithelial heterogeneity and plasticity in prostate development and cancer. The funded research analyzes lineage plasticity as a driver of tumor heterogeneity and treatment resistance in prostate cancer. The work builds on the recipient's prior studies of progenitor populations, lineage...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $153,330 on August 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop a radiotheranostic platform targeting androgen receptor in prostate cancer. The funded work develops non-steroidal androgen receptor agonists for DNA-targeted Auger electron therapy to address treatment-resistant prostate cancer. The project combines disease monitoring and targeted cytotoxic agent delivery using...
- The National Cancer Institute awarded New York University $149,190 on December 1, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support research training in biomedical careers fundamental to the National Cancer Program. The recipient, doing business as New York University School of Medicine, will conduct mechanistic research on DNA methylation and its regulation by epigenetic histone modifications. The research addresses cancer-related aberrations in DNA methylation...
- The National Cancer Institute awarded New York University $169,500 on July 3, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of LINE-1 retrotransposons in human diseases by mining patient data from the NYU Langone database, which comprises approximately 4.8 million patient records. The research will analyze reverse transcriptase inhibitor-treated patient cohorts against control cohorts to identify differences in disease incidence, integrating...